V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Integra Lifesciences Holdings Executive Compensation (FY25)

IART · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Mojdeh Poul
Median of the other named officers
$1,912,633
5 officers, excluding the chief executive
Latest say-on-pay support
=
May 7, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Integra Lifesciences Holdings brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 12, 2026Latest filing (8-K): May 8, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
The Pay Desk is the free weekly executive pay briefing — one company at a time, every number traceable to a public filing.
You’ll confirm on The Pay Desk’s sign-up page.
Integra Lifesciences Holdings brief$1,500Get the executive brief
Velarion Member, one year
331 figures on this page: 321 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Jan De Witte → Mojdeh Poul
Say-on-pay support: 98.1% → 98.8% (0.7 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Integra Lifesciences Holdings' chief executive and what were they paid?
Mojdeh Poul was paid $9,375,551 in total compensation as President and Chief Executive Officer and Director for fiscal 2025.
What was Integra Lifesciences Holdings' say-on-pay result?
The say-on-pay proposal drew 98.8% of votes cast including abstentions in favor at the meeting held May 7, 2026 for fiscal 2025.
Which companies are in Integra Lifesciences Holdings' peer group?
The disclosed peer group includes Align Technology, Inc., CONMED Corporation, Enovis Corporation, Globus Medical, Inc. and Haemonetics Corporation, among others.
What is Integra Lifesciences Holdings' chief executive pay ratio?
The company reported a chief executive pay ratio of 108.1:1 for fiscal 2025, against median employee compensation of $86,747.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jan De Witte
President and Chief Executive Officer and Director
◇—◇◇◇—◇◇
Michael McBreen
Executive Vice President, President, Codman Specialty Surgical
◇—◇◇◇—◇◇
Robert Davis Jr.
Executive Vice President, President, Tissue Technologies
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jan De Witte
President and Chief Executive Officer and Director
◇—◇◇——◇◇
Michael McBreen
Executive Vice President, President, Codman Specialty Surgical
◇—◇◇——◇◇
Lea Knight
Executive Vice President and Chief Financial Officer
◇◇◇———◇◇
Robert Davis
Executive Vice President, President, Tissue Technologies
◇—◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jan De Witte
President and Chief Executive Officer and Director
◇—◇◇◇—◇◇
Michael McBreen
Executive Vice President, President, Codman Specialty Surgical
◇◇◇◇◇—◇◇
Lea Knight
Executive Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Harvinder Singh
Executive Vice President, President, International
◇◇◇◇◇—◇◇
Robert Davis
Executive Vice President, President, Tissue Technologies
◇◇◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mojdeh Poul
President and Chief Executive Officer and Director
◇◇◇◇◇—◇◇
Lea Knight
Executive Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Michael McBreen
Executive Vice President, President, Codman Specialty Surgical
◇◇◇◇◇—◇◇
Robert Davis, Jr.
Executive Vice President, President, Tissue Technologies
◇◇◇◇◇—◇◇
Harvinder Singh
Executive Vice President, President, International
◇◇◇◇◇—◇◇
Jan De Witte
Former President and Chief Executive Officer and Director
Departed during or after this year
◇—————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Harvinder SinghPSU◇◇◇—◇—◇
Harvinder SinghRSU◇——◇——◇
Harvinder SinghOPTION◇——◇—◇◇
Lea KnightOPTION◇——◇—◇◇
Lea KnightRSU◇——◇——◇
Lea KnightPSU◇◇◇—◇—◇
Michael J. McBreenOPTION◇——◇—◇◇
Michael J. McBreenRSU◇——◇——◇
Michael J. McBreenPSU◇◇◇—◇—◇
Mojdeh PoulOPTION◇——◇—◇◇
Mojdeh PoulRSU◇——◇——◇
Mojdeh PoulPSU◇◇◇—◇—◇
Robert T. Davis JrPSU◇◇◇—◇—◇
Robert T. Davis JrRSU◇——◇——◇
Robert T. Davis JrOPTION◇——◇—◇◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jan WitteRSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Harvinder SinghRSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Michael McBreenOption◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
PSU◇◇——
Option◇—◇—
Option◇—◇—
Mojdeh PoulPSU◇◇——
RSU◇◇——
Robert DavisPSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Lea KnightOption◇—◇—
Option◇—◇—
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Mojdeh Poul
President and Chief Executive Officer and Director · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stuart M. Essig, Ph.D
Board chair
◇◇————◇
Christian S. Schade
◇◇————◇
Barbara B. Hill
◇◇————◇
Renee W. Lo
◇◇————◇
Keith Bradley, Ph.D
◇◇————◇
Shaundra D. Clay
◇◇————◇
Jeffrey A. Graves, Ph.D
◇◇————◇
Raymond L. Murphy
◇—————◇
Mojdeh Poul served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board chair premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Align Technology, Inc. ALGN
  • CONMED Corporation CNMD
  • Enovis Corporation ENOV
  • Globus Medical, Inc. GMED
  • Haemonetics Corporation HAE
  • Hologic, Inc. HOLX
  • Integer Holdings Corporation ITGR
  • LivaNova PLC LIVN
  • Masimo Corporation MASI
  • Merit Medical Systems MMSI
  • QuidelOrtho Corporation QDEL
  • ResMed, Inc. RMD
  • Steris Plc STE
  • Teleflex Incorporated TFX
  • The Cooper Companies, Inc. COO
  • West Pharmaceutical Services, Inc. WST

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 7, 2026=◇◇◇
2024May 9, 2025=◇◇◇
2023May 9, 2024=◇◇◇
2022May 12, 2023=◇◇◇
2021May 13, 2022=◇◇◇
2020May 14, 2021=◇◇◇
2019May 13, 2020=◇◇◇
2018May 16, 2019=◇◇◇
2017May 17, 2018=◇◇◇
2016May 23, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Mojdeh Poul (President and Chief Executive Officer and Director), FY2025 total compensation $9,375,551 (base salary $1,009,616) [exec_comp, SEC accession 0000917520-26-000015, filed 2026-04-06]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Integra Lifesciences Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Integra Lifesciences Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Integra Lifesciences Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Integra Lifesciences Holdings' disclosed peer group is defensible, who names Integra Lifesciences Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
331 figures on this page: 321 cited to the filing that reported them, 10 calculated from figures it prints.
321 cited to the filing
10 calculated from the filing

Documents cited

  1. 0000917520-26-000044
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000917520-26-000015
    CEO Pay Ratio Disclosure · DIRECTOR COMPENSATION · Director Compensation · Grants of Plan-Based Awards · and 3 more sections
  3. 0000917520-25-000052
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000917520-25-000032
    Summary Compensation Table
  5. 0000917520-24-000066
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000917520-24-000053
    Summary Compensation Table
  7. 0000917520-23-000032
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000917520-22-000025
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0000917520-21-000029
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0000917520-20-000022
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0000917520-19-000023
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0000917520-18-000021
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0000917520-17-000025
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Integra Lifesciences Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/IART (accessed 2026).
Short form: data: Velarion

The Integra Lifesciences Holdings brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Integra Lifesciences Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Integra Lifesciences Holdings discloses

The companies named in IART's own disclosed peer group.

Align Technology, Inc.CONMED CorporationEnovis CorporationGlobus Medical, Inc.Haemonetics CorporationHologic, Inc.Integer Holdings CorporationLivaNova PLCMasimo CorporationMerit Medical SystemsQuidelOrtho CorporationResMed, Inc.Steris PlcTeleflex IncorporatedThe Cooper Companies, Inc.West Pharmaceutical Services, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy